<SEC-DOCUMENT>0001193125-18-353328.txt : 20181219
<SEC-HEADER>0001193125-18-353328.hdr.sgml : 20181219
<ACCEPTANCE-DATETIME>20181219163636
ACCESSION NUMBER:		0001193125-18-353328
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20181218
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181219
DATE AS OF CHANGE:		20181219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tilray, Inc.
		CENTRAL INDEX KEY:			0001731348
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38594
		FILM NUMBER:		181243809

	BUSINESS ADDRESS:	
		STREET 1:		1920 EASTLAKE AVENUE E.
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		2064329325

	MAIL ADDRESS:	
		STREET 1:		1920 EASTLAKE AVENUE E.
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d661014d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;18, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Tilray, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38594</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-4310622</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1100 Maughan Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Nanaimo, BC, Canada, V9XIJ2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices and zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: <FONT STYLE="white-space:nowrap">(844)&nbsp;845-7291</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tilray Signs Global Collaboration Agreement with Leading Pharmaceutical Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2018, Tilray, Inc. (the &#147;Company&#148;) a global pioneer in the production, research, and distribution of medical cannabis, announced
that it entered into a global framework agreement (the &#147;Framework Agreement&#148;) to collaborate with Sandoz AG, a global leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high-quality
medical cannabis products across the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An evolution of an existing alliance between the Company and Sandoz Canada, the Framework Agreement
represents the intentions of the two companies to jointly operate in jurisdictions where cannabis is or will be approved for medical purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AB
InBev and Tilray Announce Research Partnership Focused on <FONT STYLE="white-space:nowrap">Non-Alcohol</FONT> THC and CBD Beverages </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;19, 2018, Anheuser Busch InBev (&#147;AB InBev&#148;), the world&#146;s leading brewer, and the Company, a global pioneer in cannabis production and distribution, issued a press release announcing a partnership to research <FONT
STYLE="white-space:nowrap">non-alcoholic</FONT> beverages containing tetrahydrocannabinol (&#147;THC&#148;) and cannabidiol (&#147;CBD&#148;). The partnership is limited to Canada, and decisions regarding the commercialization of the beverages will
be made in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research partnership combines AB InBev&#146;s deep experience in beverages with the Company&#146;s expertise in cannabis
products. AB InBev&#146;s participation will be through Labatt Breweries of Canada, one of the country&#146;s founding businesses and its leading brewery, and the Company&#146;s participation will be through its Canadian <FONT
STYLE="white-space:nowrap">adult-use</FONT> cannabis subsidiary, High Park Company, which develops, sells, and distributes a portfolio of socially responsible cannabis brands and products in Canada. Each company intends to invest up to
$50&nbsp;million USD, for a total of up to $100&nbsp;million USD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press releases noted above are filed herewith as Exhibits 99.1 and 99.2
and are incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d661014dex991.htm">Press Release issued December&nbsp;18, 2018</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d661014dex992.htm">Press Release issued December&nbsp;19, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TILRAY, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brendan Kennedy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Brendan Kennedy</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;19, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d661014dex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g661014g42t09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRESS RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tilray<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Signs Global Collaboration Agreement with Leading Pharmaceutical Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NANAIMO, B.C.</B>&#150; Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ: TLRY), a global pioneer in the production, research, and distribution of
medical cannabis, announced today that it entered into a global framework agreement (the &#147;Framework Agreement&#148;) to collaborate with Sandoz AG, a global leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to
increase availability of high quality medical cannabis products across the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An evolution of an existing alliance between Tilray and Sandoz Canada,
the Framework Agreement represents the intentions of the two companies to jointly operate in jurisdictions where cannabis is or will be approved for medical purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tilray, a global pioneer of medical cannabis, has products available in twelve countries and operations in Australia&nbsp;&amp; New Zealand, Canada, Germany,
Latin America, and Portugal. This agreement builds on Tilray&#146;s pioneering track-record as a company committed to making pharmaceutical-grade medical cannabis products available to patients <FONT STYLE="white-space:nowrap">in-need.</FONT> Tilray
was the first licensed medical cannabis producer in North America to obtain current Good Manufacturing Practice (cGMP) certification in accordance with the European Medicines Agency&#146;s (EMA) standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This agreement represents a major milestone in the movement to provide access to safe, <FONT STYLE="white-space:nowrap">GMP-certified</FONT> medical
cannabis to patients in need across the world,&#148; says Brendan Kennedy, Tilray Chief Executive Officer. &#147;Tilray is a global company and we&#146;re thrilled to build upon the success and momentum from our existing agreement with Sandoz Canada
by taking our partnership global. Sandoz AG will be a valuable partner as we work together to improve access to the highest quality medical cannabis products in countries all over the world.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Framework Agreement outlines the opportunity for the companies to agree to collaborate in different forms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sandoz AG may support the global commercialization of Tilray&#146;s
<FONT STYLE="white-space:nowrap">non-smokable/non-combustible</FONT> medical cannabis products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tilray and Sandoz AG may <FONT STYLE="white-space:nowrap">co-brand</FONT> certain
<FONT STYLE="white-space:nowrap">non-smokable/non-combustible</FONT> products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tilray&nbsp;&nbsp;|&nbsp;&nbsp;Nanaimo, BC&nbsp;&nbsp;|&nbsp;&nbsp;www.tilray.com </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g661014g42t09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRESS RELEASE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tilray may supply non-smokable/ <FONT STYLE="white-space:nowrap">non-combustible</FONT> medical cannabis products
and license rights to and from Sandoz AG in relation to such products; Both companies may also partner to leverage <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> knowledge to educate pharmacists and
physicians about medical cannabis products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tilray and Sandoz AG may collaborate to develop new innovative medical cannabis products. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Tilray<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Tilray</U>&nbsp;is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids currently serving tens of
thousands of patients in twelve countries spanning five continents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and &#147;forward-looking information&#148; within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press
release may be identified by the use of words such as, &#147;may&#148;, &#147;would&#148;, &#147;could&#148;, &#147;will&#148;, &#147;likely&#148;, &#147;expect&#148;, &#147;anticipate&#148;, &#147;believe, &#147;intend&#148;, &#147;plan&#148;,
&#147;forecast&#148;, &#147;project&#148;, &#147;estimate&#148;, &#147;outlook&#148; and other similar expressions and include statements relating to the &#151;AbB Inbev and Tilray partnership, the potential investment of each party and the
possibility of commercialization at some point in the future. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management&#146;s experience and
perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the
current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and,
accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause
actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading &#147;Risk Factors&#148; in Tilray&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> which was filed with the Securities and Exchange Commission and Canadian securities regulators on November&nbsp;14, 2018, and the risks and uncertainties related to AB InBev described under Item 3.D of AB
InBev&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed with the Securities and Exchange Commission on March&nbsp;19, 2018, for a discussion of the material risk factors that could cause actual results to differ
materially from the forward-looking information. Tilray and AB InBev does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Chrissy Roebuck<B>,
</B><U>news@tilray.com</U>, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-833-206-8161</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Katie Turner,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-646-277-1228,</FONT></FONT></FONT> <U>Katie.turner@icrinc.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tilray&nbsp;&nbsp;|&nbsp;&nbsp;Nanaimo, BC&nbsp;&nbsp;|&nbsp;&nbsp;www.tilray.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d661014dex992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g661014g86z38.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g661014g08i76.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AB InBev and Tilray Announce </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research Partnership Focused on <FONT STYLE="white-space:nowrap">Non-Alcohol</FONT> THC and CBD Beverages </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>New Partnership to Focus on Research that will Guide Responsible Innovation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TORONTO, CANADA &#150; December</B><B></B><B>&nbsp;19, 2018 &#150;</B> Today, AB InBev, the world&#146;s leading brewer, and Tilray, a global pioneer in
cannabis production and distribution, announced a partnership to research <FONT STYLE="white-space:nowrap">non-alcohol</FONT> beverages containing tetrahydrocannabinol (THC) and cannabidiol (CBD). The partnership is limited to Canada and decisions
regarding the commercialization of the beverages will be made in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research partnership combines AB InBev&#146;s deep experience in
beverages with Tilray&#146;s expertise in cannabis products. AB InBev&#146;s participation will be through its subsidiary Labatt Breweries of Canada, one of the country&#146;s founding businesses and its leading brewery, and Tilray&#146;s
participation will be through its Canadian <FONT STYLE="white-space:nowrap">adult-use</FONT> cannabis subsidiary High Park Company, which develops, sells, and distributes a portfolio of socially responsible cannabis brands and products in Canada.
Each company intends to invest up to $50&nbsp;million USD, for a total of up to $100&nbsp;million USD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Labatt is committed to staying ahead of
emerging consumer trends. As consumers in Canada explore THC and <FONT STYLE="white-space:nowrap">CBD-infused</FONT> products, our innovative drive is matched only by our commitment to the highest standards of product quality and responsible
marketing. We intend to develop a deeper understanding of <FONT STYLE="white-space:nowrap">non-alcohol</FONT> beverages containing THC and CBD that will guide future decisions about potential commercial opportunities,&#148; said Kyle Norrington,
President, Labatt Breweries of Canada. &#147;We look forward to learning more about these beverages and this category in the months ahead.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We
are delighted to be joining forces with a world-leading beverage company, AB InBev, to research how to create enjoyable cannabis beverage products. Tilray and AB InBev share a commitment to responsible product development and marketing, and we look
forward to beginning our work on this important partnership as Tilray continues to pioneer the development of a professional, transparent, and well-regulated cannabis industry,&#148; said Brendan Kennedy, CEO of Tilray. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With strong track records of responsible product development and marketing in their respective industries, AB InBev and Tilray believe that the legal market
for THC and CBD beverages will only thrive if the industry embraces appropriate regulation of <FONT STYLE="white-space:nowrap">adult-use</FONT> cannabis, including responsible production, marketing, sale and consumption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AB InBev </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AB InBev is a publicly traded company
(Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). Our Dream is to bring people
together for a better world. Beer, the original social network, has been bringing people together for thousands of years. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest natural
ingredients. Our diverse portfolio of well over 500 beer brands includes global brands Budweiser<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Corona<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Stella Artois<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; multi-country brands Beck&#146;s<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Castle<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Castle Lite<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Hoegaarden<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Leffe<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; and local champions such as Aguila<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Antarctica<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Bud Light<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Brahma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Cass<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Cristal<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Harbin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Jupiler<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Michelob Ultra<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Modelo Especial<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Quilmes<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Victoria<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Sedrin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Skol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots
at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser&nbsp;&amp; Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in
Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 180,000 employees based in nearly 50 countries worldwide. For 2017, AB InBev&#146;s reported
revenue was 56.4&nbsp;billion USD (excluding JVs and associates). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Labatt Breweries of Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established by John Kinder Labatt in London, Ontario in 1847, Labatt Breweries is one of Canada&#146;s founding businesses and its leading brewer. The company
today has more than 3,400 employees, six breweries, three stand-alone craft brewers, and a portfolio of 60 quality beers, including Budweiser, Alexander Keith&#146;s, Labatt Blue, Kokanee, Stella Artois and Corona. Brands also include <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-drink</FONT></FONT> beverages such as Palm Bay and Mike&#146;s Hard Lemonade. As part of the AB InBev family, Labatt is committed to Bringing People Together for a Better World,
making a positive contribution through multiple programs that support its communities, promote responsible drinking and protect the environment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Tilray<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tilray&nbsp;(NASDAQ:TLRY) is a global pioneer in the research, cultivation,
production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in twelve countries spanning five continents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About High Park Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based in Toronto and led by a
team with deep experience in cannabis and global consumer brands,&nbsp;<U>High Park</U><U></U>&nbsp;was established to develop, sell, and distribute a broad-based portfolio of world-class cannabis brands and products in Canada, the first <FONT
STYLE="white-space:nowrap">G-7</FONT> nation to legalize, regulate and tax for responsible adult consumption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LABATT / AB INBEV / TILRAY CONTACTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Media</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investors</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tamar Nersesian</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel: +1 416 361 5247</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email: <U>tamar.nersesian@labatt.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lauren Abbott</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel: +1 212 573 9287</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
<U><FONT STYLE="white-space:nowrap">lauren.abbott@ab-inbev.com</FONT></U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Aimee Baxter</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel: +1 718 650 4003</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
<U><FONT STYLE="white-space:nowrap">aimee.baxter@ab-inbev.com</FONT></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mariusz Jamka</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel: +32 16 276 888</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
<U><FONT STYLE="white-space:nowrap">mariusz.jamka@ab-inbev.com</FONT></U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Chrissy Roebuck</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tel: </B>+1 833 206 8161</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>news@tilray.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Jency John</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel: +1 646 746 9673</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
<U><FONT STYLE="white-space:nowrap">jency.john@ab-inbev.com</FONT></U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Katie Turner (Tilray)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel: +1 646 277 1228</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail&nbsp;:</FONT> <U>katie.turner@icrinc.com</U></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
&#147;forward-looking information&#148; within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, &#147;may&#148;,
&#147;would&#148;, &#147;could&#148;, &#147;will&#148;, &#147;likely&#148;, &#147;expect&#148;, &#147;anticipate&#148;, &#147;believe, &#147;intend&#148;, &#147;plan&#148;, &#147;forecast&#148;, &#147;project&#148;, &#147;estimate&#148;,
&#147;outlook&#148; and other similar expressions and include statements relating to the &#151;AB Inbev and Tilray partnership, the potential investment of each party and the possibility of commercialization at some point in the future.
Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management&#146;s experience and perception of trends, current conditions and expected
developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future
approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such
forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ
materially from those expressed or implied in any forward-looking statements. Please see the heading &#147;Risk Factors&#148; in Tilray&#146;s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission and Canadian
securities regulators on November 14, 2018, and the risks and uncertainties related to AB InBev described under Item 3.D of AB InBev&#146;s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 19, 2018, for a
discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray and AB InBev do not undertake to update any forward-looking statements that are included herein, except in
accordance with applicable securities laws. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g661014g08i76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g661014g08i76.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M7J*-]#US3K^/4;42IPPX9?0UYE"LJT.9'J5J3I2Y66ZW,0H * "@ H * "@
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'?2@"2@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g661014g42t09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g661014g42t09.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M.GQY6$?//(!]Q!U_'L/<UI5J*G&Y$(<[L>Q:Y<0*\.FV2B.SLE$:*O3(X_\
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MIUVDZK]X#AE^H/(I;#-"@#*\0:_:>'-,-]=AF7<$5$QN<GL,^V3^%"0')_\
M"V])_P"@?>?^._XU5A7.NT?7+?7=%74K)&96#?NC@,&'\)[9_P :G89R<GQ7
MTR&5XI--O4D0E64A001U'6JL*YU?A_7[/Q'I@O;/<J[BK(^-R$=CC\#^-3L,
MU* ,KQ!X@L_#>F_;+S<06"I&F-SGV_G32 Y6+XKZ9-*D46F7KR.0JJH4DD]
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G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g661014g86z38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g661014g86z38.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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.. 4 % !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
